- Companies
- NIOX Group
NIOX Group Valuation Multiples
NIOX Group is valued at $316M as of November 2026, a 4.5x revenue multiple. In the last 12 months, NIOX Group revenue was $66M and NIOX Group EBITDA was $23M.
NIOX Group Overview
About NIOX Group
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
Founded
2006
HQ
Employees
91
Website
Financials (LTM)
EV
$295M
Valuation Multiples
Start free trialNIOX Group Financials
NIOX Group reported last 12-month revenue of $66M and EBITDA of $23M.
In the same LTM period, NIOX Group generated $23M in EBITDA and $14M in net income.
Revenue (LTM)
NIOX Group P&L
In the most recent fiscal year, NIOX Group reported revenue of $64M and EBITDA of $20M.
NIOX Group is profitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 31%, and net margin of 14%.
Financial data powered by Morningstar, Inc.
NIOX Group Stock Performance
NIOX Group has current market cap of $316M, and enterprise value of $295M.
Market Cap Evolution
NIOX Group's stock price is $0.78.
NIOX Group share price decreased by 13.7% in the last 30 days, and by 17.4% in the last year.
NIOX Group has an EPS (earnings per share) of $0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $295M | $316M | -2.8% | -13.7% | -15.3% | -17.4% | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNIOX Group Valuation Multiples
NIOX Group trades at 4.5x EV/Revenue multiple, and 12.9x EV/EBITDA.
EV / Revenue (LTM)
NIOX Group Financial Valuation Multiples
As of November 21, 2026, NIOX Group has market cap of $316M and EV of $295M.
NIOX Group has a P/E ratio of 22.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NIOX Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


NIOX Group Margins & Growth Rates
NIOX Group grew revenue by 3% and EBITDA by 18% in the last fiscal year.
In the most recent fiscal year, NIOX Group reported gross margin of 69%, EBITDA margin of 31%, and net margin of 14%.
NIOX Group Margins
NIOX Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
NIOX Group Operational KPIs
NIOX Group's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.
NIOX Group's Rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NIOX Group's Rule of X is 43% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
NIOX Group Competitors
NIOX Group competitors include Nanjing Medlander Medical, Advanced Technology Company, Vicenne, Carvolix, VieMed, Medcaptain Medical Technology, CapsoVision, Surgical Science, Sanara MedTech and Medios.
Most NIOX Group public comparables operate across Medical Devices, Medical Imaging & Diagnostics, DeepTech and HealthTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65M | $20M | 3.3x | - | 10.6x | - | |||
| $517M | $5M | 1.7x | - | 163.5x | - | |||
| $108M | $25M | 2.8x | 2.5x | 12.0x | - | |||
| $5M | ($13M) | 71.3x | 200.6x | (24.5x) | (10.8x) | |||
| $270M | $52M | 1.2x | 1.0x | 6.3x | 5.1x | |||
| $243M | $32M | 1.3x | - | 9.9x | - | |||
| $14M | ($25M) | 22.6x | 21.3x | (12.3x) | - | |||
| $98M | $17M | 2.4x | 2.3x | 14.0x | 11.4x | |||
This data is available for Pro users. Sign up to see all NIOX Group competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by NIOX Group
NIOX Group has acquired 2 companies to date.
Last acquisition by NIOX Group was on May 15th 2015. NIOX Group acquired Aerocrine for $215M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by NIOX Group
| Description | Aerocrine is a medical device company specializing in exhaled nitric oxide measurement for airway inflammation diagnostics. Stockholm-headquartered since emerging from Karolinska Institute research in 1997, Aerocrine markets the NIOX MINO analyzer used by pulmonologists to monitor asthma and COPD in clinics across Europe, the United States and Asia. The portable device measures fractional exhaled NO levels in minutes, supporting therapy optimization. | Prosonix is a pharmaceutical technology company specializing in ultrasonic particle engineering for inhaled drugs and APIs. Oxford, United Kingdom-based, it develops crystal milling and sonocrystallization processes licensed to GlaxoSmithKline and AstraZeneca. Acquired by Hovione in 2019, Prosonix produces sub-5 micron particles improving bioavailability for dry powder inhalers used in respiratory treatments. |
| HQ Country | ||
| HQ City | Stockholm | Oxford |
| Deal Date | 15 May 2015 | 15 May 2015 |
| Valuation | $215M | $127M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all NIOX Group acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NIOX Group
| When was NIOX Group founded? | NIOX Group was founded in 2006. |
| Where is NIOX Group headquartered? | NIOX Group is headquartered in United Kingdom. |
| How many employees does NIOX Group have? | As of today, NIOX Group has over 91 employees. |
| Who is the CEO of NIOX Group? | NIOX Group's CEO is Jonathan Charles Emms. |
| Is NIOX Group publicly listed? | Yes, NIOX Group is a public company listed on London Stock Exchange. |
| What is the stock symbol of NIOX Group? | NIOX Group trades under NIOX ticker. |
| When did NIOX Group go public? | NIOX Group went public in 2014. |
| Who are competitors of NIOX Group? | NIOX Group main competitors include Nanjing Medlander Medical, Advanced Technology Company, Vicenne, Carvolix, VieMed, Medcaptain Medical Technology, CapsoVision, Surgical Science, Sanara MedTech, Medios. |
| What is the current market cap of NIOX Group? | NIOX Group's current market cap is $316M. |
| What is the current revenue of NIOX Group? | NIOX Group's last 12 months revenue is $66M. |
| What is the current revenue growth of NIOX Group? | NIOX Group revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of NIOX Group? | Current revenue multiple of NIOX Group is 4.5x. |
| What is the current EBITDA of NIOX Group? | NIOX Group's last 12 months EBITDA is $23M. |
| What is NIOX Group's EBITDA margin? | NIOX Group's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of NIOX Group? | Current EBITDA multiple of NIOX Group is 12.9x. |
| What is the current FCF of NIOX Group? | NIOX Group's last 12 months FCF is $15M. |
| What is NIOX Group's FCF margin? | NIOX Group's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of NIOX Group? | Current FCF multiple of NIOX Group is 20.3x. |
| How many companies NIOX Group has acquired to date? | As of November 2026, NIOX Group has acquired 2 companies. |
| What was the largest acquisition by NIOX Group? | $215M acquisition of Aerocrine on 15th May 2015 was the largest M&A NIOX Group has done to date. |
| What companies NIOX Group acquired? | NIOX Group acquired Aerocrine and Prosonix. |
| In how many companies NIOX Group has invested to date? | NIOX Group hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to NIOX Group
Lists including NIOX Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




